Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model
- PMID: 14638480
- PMCID: PMC296184
- DOI: 10.1128/AAC.47.12.3768-3773.2003
Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model
Abstract
We adopted an in vitro infective endocarditis model (IVIEM) to compare the efficacy of vancomycin (VAN), arbekacin (ABK), and gentamicin (GEN) alone or in combination. Using two strains of clinically isolated methicillin-resistant Staphylococcus aureus, one GEN susceptible (GS171) and one GEN resistant (GR153), fibrin clots were prepared and suspended in the IVIEM. Antibiotics were given as boluses every 6 h (q6h), q12h, or q24h or by continuous infusion with VAN, q12h or q24h with ABK, and q8h or q24h with GEN. For combination treatment, VAN q12h plus ABK q24h and VAN q12h plus GEN q24h were given. Fibrin clots were removed from each model at 0, 8, 24, 32, 48, and 72 h, and the bacterial densities were determined. The number of colonies within the fibrin clot was significantly decreased in all study groups compared with control groups (P<0.001). When VAN and ABK were administered alone, the number of colonies was significantly lower in GS171 than in GR153 by 8 h after administration (P=0.02) and was lowest in GS171 when ABK was administered q12h (P=0.01). At 72 h, ABK or VAN alone produced equivalent bacterial reductions regardless of dosing frequency and GEN resistance. In GR153, VAN plus ABK showed an additive effect till 24 h, although VAN plus GEN showed indifference. Our data suggest that ABK could be used as an alternative to VAN in GEN-resistant staphylococcal endocarditis. An additive effect was seen when VAN and ABK were used together in GEN-resistant strains until 24 h; however, further studies are warranted for the clinical application of this combination.
Figures

Similar articles
-
Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Antimicrob Agents Chemother. 1997 Nov;41(11):2497-501. doi: 10.1128/AAC.41.11.2497. Antimicrob Agents Chemother. 1997. PMID: 9371356 Free PMC article.
-
In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.Antimicrob Agents Chemother. 2000 Jul;44(7):1925-9. doi: 10.1128/AAC.44.7.1925-1929.2000. Antimicrob Agents Chemother. 2000. PMID: 10858356 Free PMC article.
-
[Treatment with arbekacin of surgical infections by resistant strains of Staphylococcus aureus. Arbekacin Study Group].Jpn J Antibiot. 1994 Jun;47(6):826-36. Jpn J Antibiot. 1994. PMID: 8072193 Clinical Trial. Japanese.
-
[Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus].Jpn J Antibiot. 1994 Jun;47(6):561-74. Jpn J Antibiot. 1994. PMID: 8072163 Review. Japanese.
-
[Drug resistance of methicillin-resistant Staphylococcus aureus (MRSA) in Japan until 1993].Jpn J Antibiot. 1994 Jun;47(6):575-84. Jpn J Antibiot. 1994. PMID: 8072165 Review. Japanese.
Cited by
-
Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus.J Korean Med Sci. 2015 Jun;30(6):688-93. doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13. J Korean Med Sci. 2015. PMID: 26028918 Free PMC article. Clinical Trial.
-
In vitro antibacterial activity and in vivo therapeutic effect of Sesbania grandiflora in bacterial infected silkworms.Pharm Biol. 2017 Dec;55(1):1256-1262. doi: 10.1080/13880209.2017.1297467. Pharm Biol. 2017. PMID: 28253823 Free PMC article.
-
The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study.Infect Chemother. 2013 Mar;45(1):62-8. doi: 10.3947/ic.2013.45.1.62. Epub 2013 Mar 29. Infect Chemother. 2013. PMID: 24265951 Free PMC article.
-
The usefulness of arbekacin compared to vancomycin.Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1663-6. doi: 10.1007/s10096-011-1490-9. Epub 2011 Nov 29. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22124537 Free PMC article.
-
Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.J Korean Med Sci. 2006 Apr;21(2):188-92. doi: 10.3346/jkms.2006.21.2.188. J Korean Med Sci. 2006. PMID: 16614499 Free PMC article.
References
-
- Aldridge, K. E., M. S. Gelfand, D. D. Schiro, and N. L. Barg. 1992. The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobials. Diagn. Microbiol. Infect. Dis. 15:601-608. - PubMed
-
- Bergeron, M. G., J. Robert, and D. Beauchamp. 1993. Pharmacodynamics of antibiotics in fibrin clots. J. Antimicrob. Chemother. 31(Suppl. D):113-136. - PubMed
-
- Blaser, J. 1985. In vitro model for simultaneous simulations of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130. - PubMed
-
- Cordeiro, J. C., A. O. Reis, E. A. Miranda, and H. S. Sader. 2001. In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals. Braz. J. Infect. Dis. 5:130-135. - PubMed
-
- Cremeiux, A., B. Maziere, J. M. Vallois, M. Ottaviani, A. Azancot, A. Raffoul, A. Bouvet, J. J. Pocidalo, and C. Carbon. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:938-944. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical